دورية أكاديمية
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network.
| العنوان: | 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. |
|---|---|
| المؤلفون: | van den Reek JM; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands., Zweegers J, Kievit W, Otero ME, van Lümig PP, Driessen RJ, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, van de Kerkhof PC, Seyger MM, de Jong EM |
| المصدر: | The British journal of dermatology [Br J Dermatol] 2014 Nov; Vol. 171 (5), pp. 1189-96. Date of Electronic Publication: 2014 Oct 03. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Oxford : Oxford University Press Original Publication: Oxford [etc.] Published for the British Association of Dermatologists by Blackwell Scientific Publications [etc.] |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*therapeutic use , Dermatologic Agents/*therapeutic use , Immunoglobulin G/*therapeutic use , Psoriasis/*drug therapy , Receptors, Tumor Necrosis Factor/*therapeutic use, Adalimumab ; Drug Substitution ; Etanercept ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Patient Satisfaction ; Prospective Studies ; Quality of Life ; Treatment Outcome ; Ustekinumab |
| مستخلص: | Background: Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality-of-life measures to drug survival have been published. Objectives: (i) To describe 1-year drug survival for adalimumab, etanercept and ustekinumab in a daily practice psoriasis cohort, and (ii) to introduce the concept of 'happy' drug survival, defined as Dermatology Life Quality Index (DLQI) ≤ 5 combined with being 'on drug' at a specific time point. Methods: Data were extracted from a prospective registry. Drug survival was analysed using Kaplan-Meier estimates. 'Happy' drug survival was calculated, with data split into 'happy' (DLQI ≤ 5) vs. 'unhappy' (DLQI > 5) at baseline and months 3, 6, 9 and 12. Results: 249 treatment episodes were included (101 adalimumab, 82 etanercept, 66 ustekinumab). The 1-year drug survival rates for ustekinumab, adalimumab and etanercept were 85%, 74% and 68%, respectively. Ustekinumab showed a better confounder-corrected drug survival vs. etanercept [hazard ratio (HR) 3·8, P = 0·02] and a trend towards better survival vs. adalimumab (HR 2·3, P = 0·1). At baseline, the majority (n = 115, 73%) was considered 'unhappy' and a minority 'happy' (n = 42, 27%) (ratio 'happy':'unhappy' was 1 : 2.7). The percentage of treatment episodes with 'happy' on-drug patients increased to 79% after 1 year. Conclusions: Ustekinumab showed a better overall drug survival than etanercept, and a trend towards a better overall drug survival than adalimumab. After 1 year, patients reported to be 'happy' in 79% of episodes and 'unhappy' in 21%. We introduced the new concept of 'happy' drug survival because the proportion of on-drug patients with good quality of life is an important indicator for treatment success. (© 2014 British Association of Dermatologists.) |
| التعليقات: | Comment in: Actas Dermosifiliogr. 2017 Sep;108(7):697-698. (PMID: 28504087) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (Dermatologic Agents) 0 (Immunoglobulin G) 0 (Receptors, Tumor Necrosis Factor) FU77B4U5Z0 (Ustekinumab) FYS6T7F842 (Adalimumab) OP401G7OJC (Etanercept) |
| تواريخ الأحداث: | Date Created: 20140509 Date Completed: 20150720 Latest Revision: 20180225 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/bjd.13087 |
| PMID: | 24807471 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2133 |
|---|---|
| DOI: | 10.1111/bjd.13087 |